Avacta Group (LON:AVCT) Issues Earnings Results

Avacta Group (LON:AVCT) posted its earnings results on Tuesday. The biotechnology company reported GBX (9.27) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The company had revenue of GBX 11 million during the quarter. Avacta Group had a negative net margin of 30,398.21% and a negative return on equity of 361.23%.

Avacta Group Price Performance

Shares of AVCT opened at GBX 80.69 on Wednesday. The firm has a market capitalization of £365.91 million, a price-to-earnings ratio of -4.60 and a beta of 1.12. The company has a debt-to-equity ratio of 14,168.75, a quick ratio of 4.96 and a current ratio of 0.79. Avacta Group has a one year low of GBX 26 and a one year high of GBX 92. The stock’s fifty day moving average is GBX 72.88 and its 200-day moving average is GBX 67.95.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).